Cargando…
Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy
BACKGROUND: Estimates of detectable antinuclear antibodies (ANA) prevalence vary widely, from 6% in healthy populations to 50–80% in patients with autoimmune disease. However, there is a lack of evidence about the overall prevalence in inflammatory bowel disease (IBD) and ANA seroconversion after th...
Autores principales: | García, María José, Rodríguez-Duque, Juan Carlos, Pascual, Marta, Rivas, Coral, Castro, Beatriz, Raso, Sandra, López-Hoyos, Marcos, Arias-Loste, María Teresa, Rivero, Montserrat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894967/ https://www.ncbi.nlm.nih.gov/pubmed/35251307 http://dx.doi.org/10.1177/17562848221077837 |
Ejemplares similares
-
Epidemiology of intrafamilial inflammatory bowel disease throughout Europe
por: Arias-Loste, Maria Teresa, et al.
Publicado: (2012) -
The Past, Present, and Future in Antinuclear Antibodies (ANA)
por: Irure-Ventura, Juan, et al.
Publicado: (2022) -
Antinuclear Antibodies
por: Frank, David A.
Publicado: (1984) -
The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease
por: Arias-Loste, María Teresa, et al.
Publicado: (2015) -
ANTINUCLEAR ANTIBODIES IN RABBIT ANTISERA
por: Barnett, Eugene V., et al.
Publicado: (1966)